Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates - Wikidata - awgldk - TriplyDB

Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates

Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates

http://www.wikidata.org/entity/Q27675168

about

The PCSK9 decade PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab The impact of genome-wide association studies on the pathophysiology and therapy of cardiovascular disease New developments in atherosclerosis: clinical potential of PCSK9 inhibition Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases Cholesterol: the good, the bad, and the ugly - therapeutic targets for the treatment of dyslipidemia Identification of a Small Peptide That Inhibits PCSK9 Protein Binding to the Low Density Lipoprotein Receptor PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling PCSK9 inhibitors - from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade.A cholesterol-lowering VLP vaccine that targets PCSK9 Determining the binding affinity of therapeutic monoclonal antibodies towards their native unpurified antigens in human serum.Common Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Epitopes Mediate Multiple Routes for Internalization and Function.Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9 PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.A method for integrative structure determination of protein-protein complexes.Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels.Immunization against proprotein convertase subtilisin-like/kexin type 9 lowers plasma LDL-cholesterol levels in mice.A Phase I Randomized Study of a Specifically Engineered, pH-Sensitive PCSK9 Inhibitor RN317 (PF-05335810) in Hypercholesterolemic Subjects on Statin Therapy.Inhibition of pro-protein convertase subtilisin kexin 9 [corrected] (PCSK-9) as a treatment for hyperlipidaemia.PCSK9 Inhibitors: potential in cardiovascular therapeutics.Evaluation of proprotein convertase subtilisin/kexin type 9: focus on potential clinical and therapeutic implications for low-density lipoprotein cholesterol lowering.Proprotein convertases subtilisin/kexin type 9, an enzyme turned escort protein: hepatic and extra hepatic functions.The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?Pharmacokinetics, Pharmacodynamics of Bococizumab, a monoclonal antibody to PCSK9, After Single Subcutaneous Injection at 3 Sites [NCT 02043301].Prospect and progress of gene therapy in treating atherosclerosis.Emerging biologic therapies for hypercholesterolaemia.The discovery of PCSK9 inhibitors: A tale of creativity and multifaceted translational research.Novel Therapies for Familial Hypercholesterolemia.A Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for Bococizumab, a Humanized Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, and Its Application in Early Clinical Development.Bococizumab for the treatment of hypercholesterolaemia.Characterization of proprotein convertase subtilisin/kexin type 9 (PCSK9) trafficking reveals a novel lysosomal targeting mechanism via amyloid precursor-like protein 2 (APLP2).Heparan sulfate proteoglycans present PCSK9 to the LDL receptor.Combined administration of RG7652, a recombinant human monoclonal antibody against PCSK9, and atorvastatin does not result in reduction of immune function.Nonhuman Primates and Translational Research-Cardiovascular Disease.The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorv Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin.

P2860

Q24615397-85C0DD5B-9122-4332-BD21-1DBE0B671AEE Q26747776-B90E340F-1651-490B-A360-923F50820B42 Q26748869-3A33EBC3-DBDE-4910-835F-F17F957D3441 Q26783407-98DF2DCC-A8B9-4545-9E48-B33737510A2E Q27009477-53E01A0B-D99B-4745-9273-A7AA38A4C6A5 Q27013494-0CF8F23D-7B35-44DB-9A2B-B3FF525BA14F Q27680601-2EDB1824-D32F-4685-B360-94DCF9E61327 Q28586625-BD89636C-D3AD-4FBB-AAED-5C12D4771FD2 Q33904455-319AECEE-94ED-49C7-B43F-4D83BD660B62 Q34496015-45EEEAAE-90F6-4212-BD4F-30CE63168984 Q35040430-B362FF19-4828-43F8-93B1-687857D96A05 Q35612555-326B1A06-5F8B-45D0-B64F-DBF083F35902 Q35879455-D289416B-E289-49AE-893B-303E13DB910E Q36196833-519D8070-E51D-48E0-BD85-2BA57A43626B Q36459249-D1AE78B3-0228-40FA-86F3-B43FF8E8E47F Q36481769-3B5316C3-811F-4014-AA28-BFE4DE47935A Q36520347-8D33E8CC-A976-46D9-BA21-85E72DB865C4 Q37700671-6A41AEC5-4671-4C2E-85D7-DF9F29717422 Q38001736-6322BD00-B895-4EFC-B032-03A5C397A8CC Q38075818-6EF0AD20-BF29-4AFF-9953-02880FDD1459 Q38095872-F8CABE19-A380-41C9-AD24-301CA2DD5739 Q38109960-86CE9D3D-91ED-4FCB-B937-70352947B2E6 Q38151675-6C4264A2-D187-4836-A2F7-8B2251679480 Q38221015-A25C4E0D-2F0E-4F38-8BA3-362B8521D039 Q38375213-59B841BB-9213-446D-8923-C32CD8579905 Q38578275-4D5A3A66-2E8C-4DCD-8C3B-936D8126ECF8 Q38724666-24F60DA6-AD41-41A6-BAA4-101586309EB2 Q38821139-6970BD07-D950-4980-A0B5-76D4D537636E Q38952663-DB2E537F-2837-41F7-8DB0-409B0475D88A Q38970474-D14A5F3B-5005-4E49-839B-401149881AF7 Q39035931-5933F5B2-2604-40FE-AEAF-38B19E5261D2 Q39795723-35425F4E-9753-41F7-9290-2454E023C5A1 Q41328708-647241CE-E329-4C18-919F-0B1A5ED33C90 Q43568688-F79C69C7-89DA-4495-8609-06310AED52B6 Q46292627-8FBC3023-6FDE-4E7B-8D56-BF8A3DAE7FB6 Q48113239-879E587C-0B0C-4AAD-95D8-D3BE2BF43D12 Q48149515-70248756-5030-4B07-A048-0EAB6109E7F1

P2860

Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates

http://www.wikidata.org/entity/Q27675168

description

2012 nî lūn-bûn

@nan

2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Proprotein convertase substili ...... lesterolemic nonhuman primates

@ast

Proprotein convertase substili ...... lesterolemic nonhuman primates

@en

Proprotein convertase substili ...... lesterolemic nonhuman primates

@nl

type

label

Proprotein convertase substili ...... lesterolemic nonhuman primates

@ast

Proprotein convertase substili ...... lesterolemic nonhuman primates

@en

Proprotein convertase substili ...... lesterolemic nonhuman primates

@nl

prefLabel

Proprotein convertase substili ...... lesterolemic nonhuman primates

@ast

Proprotein convertase substili ...... lesterolemic nonhuman primates

@en

Proprotein convertase substili ...... lesterolemic nonhuman primates

@nl

P1433

Q27675168-D11F56B1-3345-4382-A26C-8FA443889FDE

P1476

Q27675168-D10E946F-5EC2-46D0-862B-504C47E2C56A

P2093

Q27675168-298C9426-64C5-42A8-A660-C7DE4FF68367

Q27675168-2BAC8F14-71AD-435D-8E3F-A505B3C6E503

Q27675168-2D13F6CA-4F23-40EF-BB49-E8E515069555

Q27675168-342DEB11-CF8D-40BB-B8F9-962E9F595B4A

Q27675168-3EE5212E-3442-4388-8893-AD0E1892465E

Q27675168-51ACC9DC-6C7A-4313-A0D9-3C8E645239B4

Q27675168-56EAFBB0-CE99-47C1-977A-72E553A8C739

Q27675168-5B4F1B2C-2F53-4A6A-8987-51CFC40FDECE

Q27675168-69446676-943B-4BBC-A026-51151B39C260

Q27675168-788EEE88-F29F-44CB-96D9-B3CCEB51B81F

P304

Q27675168-06432EFC-E910-44F5-A50B-68523B27B768

P31

Q27675168-023C3566-F461-4E8E-BAC2-A706A2BE2D49

P3181

Q27675168-7400CFB3-E399-46F6-9B3F-5AFF26F48ABD

P356

Q27675168-B9384DAC-88DB-4D31-A347-65711B34E5C9

P407

Q27675168-BB23B00E-03EB-4780-B9ED-530D1C5D870F

P433

Q27675168-038FAB80-726F-41BD-B9E2-7A73068DEE84

P478

Q27675168-D3FF65A8-8F9C-437B-879B-8593B1C274D3

P577

Q27675168-FEBF1186-CEE7-422D-8858-35732931AEE7

P5875

Q27675168-73DDF647-9404-4CF7-AC47-92FC5227F124

P698

Q27675168-FD955256-5E23-45E2-BDC6-1BE074390FB4

P921

Q27675168-31781884-1549-4844-823C-0EC857A2556E

Q27675168-D2DAC2AC-3116-4FB6-ACB1-A64231420D7D

Q27675168-D67A72E2-D764-4A83-A361-4DCCFEE292EF

P3181

P356

JPET.111.187419

P1433

Journal of Pharmacology and Experimental Therapeutics

P1476

Proprotein convertase substili ...... lesterolemic nonhuman primates

@en

P2093

Andrea Rossi

http://www.w3.org/2001/XMLSchema#string

Arvind Rajpal

http://www.w3.org/2001/XMLSchema#string

Daniel Tsai

http://www.w3.org/2001/XMLSchema#string

David L Shelton

http://www.w3.org/2001/XMLSchema#string

Hong Liang

http://www.w3.org/2001/XMLSchema#string

Janette E Sutton

http://www.w3.org/2001/XMLSchema#string

Jaume Pons

http://www.w3.org/2001/XMLSchema#string

Javier Chaparro-Riggers

http://www.w3.org/2001/XMLSchema#string

Jeanette Dilley

http://www.w3.org/2001/XMLSchema#string

Jessica Yu

http://www.w3.org/2001/XMLSchema#string

P304

228-36

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1767679

http://www.w3.org/2001/XMLSchema#string

P356

10.1124/JPET.111.187419

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

340

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51742145

http://www.w3.org/2001/XMLSchema#string

P698

22019884

http://www.w3.org/2001/XMLSchema#string

P921

LDL cholesterol

hypercholesterolemia